Locket Healthcare Registers AI Organ Regeneration Platform with US FDA... "Will Innovate AI Medical Market"

[Asia Economy Reporter Hyunseok Yoo] Global bio-specialized company Rokit Healthcare announced on the 10th that it has completed the medical device registration of its artificial intelligence (AI) organ regeneration platform ‘AiD Regen’ with the U.S. Food and Drug Administration (FDA).

‘AiD Regen’ is a cloud-based organ regeneration platform. After capturing the surgical site of a patient in the operating room, the AI recognizes the location and shape of the affected area to create a three-dimensional model. A 4D bio printer then outputs a regenerative patch that can be implanted into the affected area.

A company official explained, “The simplified surgical process through AI automation allows highly precise medical devices to be handled easily and safely with just a few touch operations.”

Rokit Healthcare pioneered the regenerative treatment field by combining the ‘AiD Regen’ platform with the 4D bio printer ‘Dr. INVIVO 4D.’ The company official said, “Using our treatment method, we expect to treat more patients due to time and cost savings, such as reducing diabetic foot treatment costs by about 90% compared to the average 12-week dressing costs.”

‘AiD Regen’ plans to expand its treatment scope beyond diabetic foot to cartilage, kidney, burns, and pressure ulcers. The company explained that as the world’s first AI-based self-regeneration platform, it is expected to solve the challenges of regenerative medicine.

The AiD Regen platform automates detailed processes including ▲ AI-based detection of affected areas, ▲ boundary extraction (Segmentation), ▲ three-dimensional modeling (3D Modeling), and material optimization (Optimization). Utilizing this platform can also alleviate the difficulty medical staff face in acquiring skills when applying existing advanced technologies.

Yuseokhwan, CEO of Rokit Healthcare, said, “‘AiD Regen’ was developed in compliance with the U.S. Health Insurance Portability and Accountability Act and the European Union’s General Data Protection Regulation, keeping overseas market entry in mind,” adding, “We will demonstrate innovation in the AI medical market through aggressive marketing and leveraging our sales network.”